10-Q: Allakos Inc. Reports Third Quarter 2024 Financial Results and Provides Clinical Development Update

Allakos Inc. announced its third quarter 2024 financial results, highlighting progress in its AK006 clinical program and a reduction in operating expenses following a company reorganization.

Summary

• Allakos Inc. reported a net loss of $116.2 million for the nine months ended September 30, 2024, compared to a net loss of $123.2 million for the same period in 2023.
• The company's research and development expenses decreased to $65.1 million for the nine months ended September 30, 2024, from $97.1 million in the same period of 2023, primarily due to the halt of lirentelimab development.
• General and administrative expenses also decreased to $29.0 million for the nine months ended September 30, 2024, from $34.0 million in the same period of 2023.
• Allakos recorded a $27.3 million impairment charge on long-lived assets during the nine months ended September 30, 2024, due to a decline in the company's stock price after halting lirentelimab development.
• As of September 30, 2024, Allakos had $92.7 million in cash, cash equivalents, and investments, which the company believes is sufficient to fund operations for at least the next 12 months.
• The company is focusing on the development of AK006, with initial data from a Phase 1 trial in chronic spontaneous urticaria (CSU) expected in early Q1 2025.
• Positive results were reported from Phase 1 trials of both intravenous and subcutaneous AK006 in healthy volunteers, showing high receptor occupancy on mast cells and a favorable safety profile.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in the AK006 program and cost-cutting measures, the significant net losses, impairment charges, and need for additional funding temper the overall sentiment. The company's future success is heavily reliant on the success of AK006.

Positives

• The company's cash position of $92.7 million is expected to fund operations for at least the next 12 months.
• The company has successfully developed a subcutaneous formulation of AK006 with good bioavailability.
• Phase 1 trials of AK006 have shown promising results with high receptor occupancy and a favorable safety profile.
• Operating expenses have decreased due to the reorganization plan and halting of lirentelimab development.
• The company is focusing on AK006, which has shown potential in preclinical studies for mast cell diseases.

Negatives

• The company has incurred significant net losses since inception and expects to continue to do so for the foreseeable future.
• The company recorded a $27.3 million impairment charge on long-lived assets.
• The company has an accumulated deficit of $1,234.7 million.
• The company has no products approved for sale and has not generated any revenue.
• The company is reliant on additional capital to fund operations.

Risks

• The company is subject to risks associated with clinical trials, regulatory approvals, and commercialization of product candidates.
• The company may not be able to obtain additional funding on acceptable terms or at all.
• The company's stock price may be volatile and subject to delisting if it fails to maintain compliance with Nasdaq listing requirements.
• The company is reliant on third parties for manufacturing and clinical trials.
• The company faces competition from other biopharmaceutical companies.

Future Outlook

The company expects to report initial data from the AK006 Phase 1 trial in CSU patients in early Q1 2025 and plans to use the subcutaneous formulation of AK006 in subsequent clinical development. The company believes its current cash position is sufficient to fund operations for at least the next 12 months.

Management Comments

• Management believes that the current cash, cash equivalents and investments will be sufficient to fund planned operations for at least the next 12 months.
• Management expects to incur additional operating losses in the future as the company continues to develop its product candidates.
• Management believes the 2024 Reorganization Plan will reduce overall spending in subsequent quarters.

Industry Context

This announcement comes as the biopharmaceutical industry continues to focus on developing novel therapies for inflammatory and allergic diseases. Allakos' focus on mast cell inhibition with AK006 aligns with the growing interest in targeted therapies for these conditions. The company's decision to halt lirentelimab development and focus on AK006 reflects a strategic shift in response to clinical trial results, a common occurrence in the industry.

Comparison to Industry Standards

• The decrease in R&D spending is consistent with other companies that have streamlined their pipelines after clinical trial setbacks, such as when a company discontinues a drug candidate.
• The reported cash runway of 12 months is a common metric used by investors to assess the financial stability of clinical-stage biotech companies, with many companies aiming for 12-24 months of cash on hand.
• The focus on subcutaneous administration of AK006 is in line with industry trends towards more convenient drug delivery methods, similar to companies developing injectable biologics.
• The company's Phase 1 trial results for AK006 are comparable to other early-stage clinical trials in terms of safety and receptor occupancy, but further data is needed to assess efficacy.
• The company's decision to halt lirentelimab development is similar to other companies that have had to make strategic decisions based on clinical trial results, such as when a drug fails to meet its primary endpoints.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may have been impacted by the workforce reduction as part of the reorganization plan.
• Customers (potential patients) may benefit from the development of AK006 if it proves to be an effective treatment.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to report initial data from the AK006 Phase 1 trial in CSU patients in early Q1 2025.
• The company will continue to develop the subcutaneous formulation of AK006 for future clinical trials.
• The company will continue to seek additional funding to support its operations and development programs.

Key Dates

Keywords

AK006, mast cells, clinical trial, biopharmaceutical, immunomodulatory, urticaria, research and development, financial results, reorganization, Siglec-6